ProCE Banner Activity

ROCKstar Phase II Trial of Daily or Twice-Daily Belumosudil (KD025) in Previously Treated Patients With Chronic GVHD

Slideset Download
Conference Coverage
In patients with cGVHD after alloSCT and 2-5 prior lines of systemic therapy, belumosudil was well tolerated with response rates > 70% and a median DoR of 50 weeks.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology